Showing 3141-3150 of 5646 results for "".
- Complexity Gaming Kicks Off Year-Long Partnership With Alconhttps://modernod.com/news/complexity-gaming-kicks-off-year-long-partnership-with-alcon/2479475/Esports company Complexity Gaming announced a partnership with Alcon. The partnership will designate Alcon’s signature brand of lubricant eye drops, Systane, as the first official eye care partner of Complexity Gaming. Now more than ever, dry eye symptoms are affecting people due to increa
- Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme/2479451/Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of t
- US Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry AMDhttps://modernod.com/news/us-phase-2-study-published-in-osli-retina-highlights-the-safety-and-efficacy-of-risuteganib-in-patients-with-dry-amd/2479429/Allegro Ophthalmics announced that the results of the company’s US phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina. Entitled
- Aurion Biotech Announces IOTA Cell Therapy Trialhttps://modernod.com/news/aurion-biotech-announces-iota-cell-therapy-trial/2479415/Aurion Biotech announced preliminary findings from its IOTA trial, conducted in November 2020 and in May of this year, at the Clínica Quesada in San Salvador, El Salvador. In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell th
- New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopiahttps://modernod.com/news/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia/2479409/Allergan announced new data, including the full results from the phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. Multiple data presentations at the 2021
- United Nations Resolution Designed to Tackle Preventable Sight Losshttps://modernod.com/news/united-nations-resolution-designed-to-tackle-preventable-sight-loss/2479406/The United Nations General Assembly (UNGA) has adopted
- Alcon Reinforces Strength of Ophthalmology Portfolio With Surgical Device Scientific Presence at ASCRShttps://modernod.com/news/alcon-reinforces-strength-of-ophthalmology-portfolio-with-surgical-device-scientific-presence-at-ascrs/2479398/Alcon will present a breadth of data during the American Society of Cataract and Refractive Surgery (ASCRS) 2021 annual meeting, taking place July 23-27 in Las Vegas. More than 60 abstracts featuring Alcon ophthalmic products and equipment will be presented. The full abstract book, registration l
- Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-Cleared AI Technology for Detection of Diabetic Retinopathyhttps://modernod.com/news/eyenuk-announces-6-2-million-financing-to-accelerate-adoption-of-fda-cleared-ai-technology-for-detection-of-diabetic-retinopathy/2479388/Eyenuk announced that it has completed a financing round of $6.2 million to accelerate commercialization of the EyeArt AI System, which received FDA clearance in 2020 and is being reimbursed by Medicare and other payo
- FDA Sets January Deadline to Decide on Full Approval of Pfizer, BioNTech Vaccinehttps://modernod.com/news/fda-sets-january-deadline-to-decide-on-full-approval-of-pfizer-biontech-vaccine/2479380/Pfizer and BioNTech said that the FDA has granted a priority review for an application seeking full approval of their vaccine BNT162b2 to prevent COVID-19 in people 16 years and older, according to a FirstWord
- Harrow Health Granted Two Patents for Novel Surgical Dilation Formulationhttps://modernod.com/news/harrow-health-granted-two-patents-for-novel-surgical-dilation-formulation/2479377/Harrow Health announced that the United States Patent and Trademark Office issued two patents, entitled “Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof.” Harrow Health’s wholly owned subsidiary, ImprimisRx, provides surgical dilation (